E-LIB Suche - Ergebnisse für: Rothenstein, D.

1

EP08.02-034 OCELOT - Osimertinib then Chemotherapy in EGFR+..:

Breadner, D. ; Liu, G. ; Rothenstein, J....
Journal of Thoracic Oncology. 17 (2022) 9 - p. S412-S413 , 2022

Link: https://doi.org/10.1016/..

2

A phase I study of binimetinib (MEK 162), a MEK inhibitor, ..:

Fung, A.S. ; Graham, D.M. ; Chen, E.X....
Lung Cancer. 157 (2021) - p. 21-29 , 2021

Link: https://doi.org/10.1016/..

3

Perspectives on Treatment Advances for Stage III Locally Ad..:

Cheema, P.K. ; Rothenstein, J. ; Melosky, B...
Current Oncology. 26 (2019) 1 - p. 37-42 , 2019

Link: https://doi.org/10.3747/..

4

Perspectives on treatment advances for stage III locally ad..:

Cheema, P. K. ; Rothenstein, J. ; Melosky, B...
Current Oncology. 26 (2019) 1 - p. , 2019

Link: https://doi.org/10.3747/..

5

Canadian Consensus: Oligoprogressive, Pseudoprogressive, an..:

Laurie, S.A. ; Banerji, S. ; Blais, N....
Current Oncology. 26 (2019) 1 - p. 81-93 , 2019

Link: https://doi.org/10.3747/..

6

Real-World Benefit of Nivolumab in A Canadian Non-Small-Cel..:

Juergens, R.A. ; Mariano, C. ; Jolivet, J....
Current Oncology. 25 (2018) 6 - p. 384-392 , 2018

Link: https://doi.org/10.3747/..

7

Treatment Patterns and Survival in Patients with ALK-Positi..:

Kayaniyil, S. ; Hurry, M. ; Wilson, J....
Current Oncology. 23 (2016) 6 - p. 589-597 , 2016

Link: https://doi.org/10.3747/..

8

Generation of luminescence in biomineralized zirconia by zi..:

Rothenstein, D. ; Shopova-Gospodinova, D. ; Bakradze, G...
CrystEngComm. 17 (2015) 8 - p. 1783-1790 , 2015

Link: https://doi.org/10.1039/..

9

Management of egfr tki—Induced Dermatologic Adverse Events:

Melosky, B. ; Leighl, N.B. ; Rothenstein, J....
Current Oncology. 22 (2015) 2 - p. 123-132 , 2015

Link: https://doi.org/10.3747/..

10

Capecitabine Plus Mitomycin in Patients Undergoing Definiti..:

Goodman, K.A. ; Rothenstein, D. ; Lajhem, C....
International Journal of Radiation Oncology*Biology*Physics. 90 (2014) 1 - p. S32-S33 , 2014

Link: https://doi.org/10.1016/..

11

Prevalence of Patient-Reported Gastrointestinal Symptoms an..:

Tom, A. ; Bennett, A. ; Rothenstein, D....
International Journal of Radiation Oncology*Biology*Physics. 87 (2013) 2 - p. S570-S571 , 2013

Link: https://doi.org/10.1016/..

12

Predictors of Outcome and Toxicities of Definitive Chemorad..:

Rothenstein, D. ; Oh, J. ; Apte, A....
International Journal of Radiation Oncology*Biology*Physics. 87 (2013) 2 - p. S335 , 2013

Link: https://doi.org/10.1016/..

13

Biodiversity and recombination of cassava-infecting begomov..:

Rothenstein, D. ; Haible, D. ; Dasgupta, I....
Archives of Virology. 151 (2005) 1 - p. 55-69 , 2005

Link: https://doi.org/10.1007/..

14

Biolistic infection of cassava using cloned components of I..:

Rothenstein, D. ; Briddon, R. W. ; Haible, D....
Archives of Virology. 150 (2005) 8 - p. 1669-1675 , 2005

Link: https://doi.org/10.1007/..

15

Exposure data for cosmetic products: lipstick, body lotion,..:

Loretz, L.J. ; Api, A.M. ; Barraj, L.M....
Food and Chemical Toxicology. 43 (2005) 2 - p. 279-291 , 2005

Link: https://doi.org/10.1016/..